[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.168.87. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Observation
May 2003

Basal Cell Carcinoma With Pulmonary and Lymph Node Metastasis Causing Death

Author Affiliations

From the Departments of Medicine (Dr Robinson) and Pathology (Drs Robinson and Dahiya), Loyola University Stritch School of Medicine, Maywood, Ill. The authors have no relevant financial interest in this article.

Arch Dermatol. 2003;139(5):643-648. doi:10.1001/archderm.139.5.643
Abstract

Background  The incidence of metastatic basal cell carcinoma ranges from 0.003% to 0.55%. The 230 reported cases most often occurred in long-standing recurrent lesions and appeared in regional nodes or the lungs.

Observations  The stromal dependence of the tumor provides an explanation for the nonmetastasizing nature of basal cell carcinoma. The dense fibrous stroma of the lymph node in the case of metastatic basal cell carcinoma reported in the present study is similar to other reported cases with metastases to lymph nodes, bone, bone marrow, glands, and subcutaneous tissue.

Conclusions  This metastatic basal cell carcinoma demonstrated lymphatic and hematogenous dissemination to the lungs and lymph nodes. A dense accumulation of microvessels was present at the boundary of the tumor nests and dermal stroma and in the stroma surrounding the tumor in the lymph node.

THE REPORTED incidence of metastatic basal cell carcinoma (MBCC) ranges from 0.003% to 0.55%.15 The range is in part due to the lack of accurate data for the incidence of basal cell carcinoma (BCC), which has an estimated incidence of 900 000 to 1 200 000 in the United States,6 but is excluded from traditional national cancer registries, such as Surveillance, Epidemiology and End Results. In the New Mexico Registry, the 1991 BCC incidence was 1359 per 100 000 for white men and 502 per 100 000 for white women.7

While BCC is a slow-growing, usually nonmetastazing but invasive tumor, at least 230 cases fulfilling the criteria for MBCC were reported in the literature.8,9 Metastasis to regional nodes or lungs occurred in long-standing recurrent lesions.1 According to Pinkus,10 the stromal dependence of the tumor provides an explanation for the nonmetastasizing nature of BCC. We report a case of MBCC with dense fibrous stroma in the lymph node and microvessels defined by CD34 at the boundary of the tumor and stroma.

REPORT OF A CASE

A 55-year-old man presented for Mohs surgical resection of a BCC of the right posterior upper shoulder in 1984 that recurred after 2 previous treatments. The tumor was initially treated with electrodesiccation and curettage in 1980, and the recurrence was excised in 1982. He presented for care with a 3.2 × 3.8-cm scar on the right posterior shoulder having clinically apparent recurrent BCC in the lateral part of the scar (Figure 1A). The Mohs surgical resection of this T3 tumor was 24.6 cm2 (diameter of resection, 6.0 × 4.1 cm) and extended into the muscle. The infiltrating BCC penetrated the fascia and extended between the muscle bundles (Figure 1B). Perineural spread was not seen; however, BCC was present within the lumen of an artery within the muscle (Figure 2). Complete blood count and findings from liver function tests, chest radiography, bone scan, and computed tomography of the chest, brain, and abdomen were normal.

Figure 1.
A, The right ear appears above the shoulder that has a recurrent basal cell carcinoma (arrows mark the tumor). B, Dense stroma surrounding the infiltrating basal cell carcinoma in the dermis (hematoxylin-eosin, original magnification ×10).

A, The right ear appears above the shoulder that has a recurrent basal cell carcinoma (arrows mark the tumor). B, Dense stroma surrounding the infiltrating basal cell carcinoma in the dermis (hematoxylin-eosin, original magnification ×10).

Figure 2.
A, Basal cell carcinoma surrounds the artery and fills the lumen of the intramusclar vessel (hematoxylin-eosin, original magnification ×20). B, Antikeratin immunoperoxidase staining demonstrates that the embolus is composed of keratinocytes (antikeratin immunoperoxidase, original magnification ×20).

A, Basal cell carcinoma surrounds the artery and fills the lumen of the intramusclar vessel (hematoxylin-eosin, original magnification ×20). B, Antikeratin immunoperoxidase staining demonstrates that the embolus is composed of keratinocytes (antikeratin immunoperoxidase, original magnification ×20).

Five years after surgery, in 1989, there was no recurrence at the site of the resection on the shoulder, but the patient developed a 1.6-cm, firm, palpable right axillary node. Complete blood count and findings from liver function tests, chest radiography, bone scan, and computed tomography of the chest, brain, and abdomen were normal. Axillary lymph node dissection was positive for MBCC in 2 of 5 nodes. The histologic pattern resembled that of the tumor of the skin of the right shoulder with infiltrating BCC with fibrous stroma.

During the node dissection, the tumor was adherent to the axillary vein and could not be resected. The axilla was treated with 4500 rad (45 Gy) of local radiation, and the area of tumor adherent to the axillary vein received a total of 6600 rad (66 Gy) over 3 months. This right-handed man developed severe lymphedema of the right arm. In spite of daily treatment with a 10-chamber compression pump (Lymphapress; MegoAfek, Kibbutz Afek, Israel) and a Jobst garment, the use of his hand was severely limited. In 1994, radionecrosis of the axillary vault caused acute arterial bleeding, which was repaired with an arterial graft. There was constant lymphatic axillary drainage, which required packing with absorbent material. He died in 1997, 8 years after the axillary dissection, from hemorrhaging into pulmonary metastases.

METHODS
HISTOLOGIC ANALYSIS

Surgical samples of the lymph node were fixed in 10% formalin and embedded in paraffin. Selected Mohs surgical specimens were also fixed in formalin and embedded in paraffin. Paraffin embedded 5-µm sections were cut and stained with hematoxylin-eosin. Infiltrating BCC was surrounded by dense stroma in lymph node and the dermis.

IMMUNOHISTOCHEMICAL ANALYSIS

Immunohistochemical staining was performed on deparaffinized tissue sections cut at 5 µm by the Ventana automated method. The following mouse antibodies were used: CEA (Ventana, Tuscon, Ariz), CK-pan (Ventana), EMA (Ventana), Bcl-2 (Ventana), CK-7 (Ventana), CD31 (Ventana), CD34 (Ventana), and Ber Ep4 (Biocare Medical, Walnut Creek, Calif).

Tumor specimens from the recurrent tumor in the skin and from the MBCC in the axillary lymph node were examined with a serial immunopanel (CEA, CK-pan, EMA, Bcl-2, CK-7, and Ber Ep4) to determine the cell of origin of the tumor and demarcate the endothelial cells (CD31 and CD34) forming the microvasculature (Table 1). The intense Ber Ep4 expression by tumor cells supports a diagnosis of BCC; the negative staining for EMA argues against a basosquamous cell carcinoma. Similarly, the negative CEA and very weak focal cytokeratin 7 expression, combined with the characteristic histologic features of the tumor nests, argues against a metastatic breast or lung carcinoma. The CD31 and CD34 highlights the pattern of microvasculature hugging the interface of the tumor nests and the stroma in both specimens (Figure 3B and C). Occasional microvessels were apparent within the tumor nests.

Table 1. 
Immunohistochemical Expression by the Tumor
Immunohistochemical Expression by the Tumor
Figure 3.
A, Infiltrating basal cell carcinoma surrounded by dense stroma in lymph node (hematoxylin-eosin, original magnification ×10). B and C, The CD34 delineates microvessels cuffing the dermal interface of the tumor nests (B) and microvessels within tumor nests (C) in the metastatic basal cell carcinoma in the lymph node (CD34 immunoperoxidase, original magnification ×20).

A, Infiltrating basal cell carcinoma surrounded by dense stroma in lymph node (hematoxylin-eosin, original magnification ×10). B and C, The CD34 delineates microvessels cuffing the dermal interface of the tumor nests (B) and microvessels within tumor nests (C) in the metastatic basal cell carcinoma in the lymph node (CD34 immunoperoxidase, original magnification ×20).

MBCC REPORTED IN THE LITERATURE

Most of the 230 reported cases of MBCC during the period 1894 to 2000 were identified in the last 30 years.11,12 A total of 140 cases provided a photomicrograph or described the stroma of the primary tumor and the stroma in the lymph node metastasis; 42 cases described the stroma in the visceral metastasis as mucinous fibrous tissue surrounding the islands of BCC. The fibrotic stroma surrounding the MBCC was described as dense (lymph node, bone, bone marrow, or salivary and parotid glands) sparse (lung or liver), or not present (adrenal gland, spleen, or brain).

COMMENT

The incidence of MBCC ranges from 0.01% in pathologic specimens4 through 0.03% in dermatology patients2 to 0.1% in data from surgical centers.1 Variation in the reported incidence may be due to selection bias from the sources of the data and exclusion of BCC from traditional cancer registries in the United States. In the Danish registry, the estimated lethality of BCC is 0.12%, which may be inferred to be principally from MBCC and local infiltrative growth into vital structures.13 The criteria for the 230 reported MBCC cases were that the primary tumor is from skin and not mucous membranes or glandular or other origin; metastasis occurred in a site distant from the primary tumor and cannot be a result of direct extension, and both metastatic and primary lesions must have similar histologic subtypes.

While the usual MBCC is a large, ulcerated, locally invasive BCC of the head and neck that recurs despite repeated surgical procedures or radiotherapy,14 these features are not absolute prerequisites for metastasis.15 Immunosuppression does not appear to be a cause of MBCC.16 In one review of 170 cases, the median interval between onset of BCC and metastasis was 9 years, with a range of less than 1 year to 45 years.16 Despite the long period from onset to metastasis, the tumor behaves aggressively once metastasis occurs. In the same review, 8 months after the first symptoms of metastasis, half of the patients were deceased.16 Our case had a 9-year period from onset of the BCC to metastasis, and the patient survived for an additional 8 years from discovery of the lymph node metastasis until his death.

While some believe that metatypical or basosquamous-type BCC is the most likely to metastasize,17 most report no specific histologic type of BCC as more capable of metastasizing.1820 Perineural spread and invasion of blood vessels by BCC (Figure 2) enhance the likelihood of metastasis.16 Vascular lumina large enough to transmit tumor emboli are commonly located at or deep to the fascia over the muscle. While BCC invades blood vessels and may be present intraluminally, the tumor cells may not survive the physical changes induced by circulation to remain viable and implant in a capillary bed. In addition, immunologic surveillance may impair tumor growth at a distant site.

Metastasis may depend on the size of the original tumor and the depth of tumor invasion.21,22 Tumors greater than 3 cm in diameter have a 2% incidence of metastasis and/or death. This increases to 25% in those lesions more than 5 cm in diameter and to 50% in lesions more than 10 cm in diameter.23 Primary tumors invaded deeply into extradermal structures, such as cartilage, skeletal muscle, or bone.23 There were only 2 case reports of BCC smaller than 1 cm in diameter leading to metastasis.24,25

About half of MBCC have metastasis to lymph nodes as the first site, but the hematogenous route to lungs and bones is also equally represented.16 Metastases to liver, other viscera, and subcutaneous tissues may occur, but these areas were usually involved when lymph nodes, lungs, or bones were also affected.26,27 Once distant spread occurs, response to chemotherapy with methotrexate, fluorouracil, bleomycin, and cisplatin is marginal, and survival rarely exceeds 1.5 years.28

Basal cell carcinoma has a keratin pattern resembling the outer root sheath of the hair follicle below the isthmus and/or the bulge region of the vellus hair follicle, rather than that of the basal cell epithelium.29,30 This keratin pattern supports the follicular origin of BCC. The follicular origin of BCC may explain the stromal dependency of BCC noted in the 1960s. Stromal dependent tumor maturation is governed by the connective tissue in its proximity.31 Lyles et al32 in 1960 and Blackwell and McComb33 in 1969 performed autotransplantation of BCC in human volunteers with little to no success. In 1961, Van Scott and Reinertson31 also failed when transplanting only the epithelial parts of BCC, but when the stroma was included with the epithelial parts of BCC, some transplantations succeeded in human volunteers. Transplantation of BCC into the anterior chamber of the rabbit's eye and the intrauterine cavity of the rat was unsuccessful.34,35 It is believed that failure of BCC to grow in tissue culture may be related to its stromal dependence. Grimwood and colleagues' successful transplantation of human BCC with its stroma into nude mice reinforces the stromal dependency of BCC.36

Given the probable follicular origin of BCC, surgical experience with hair transplantation provides a model for survival of metastatic cells at distant locations. Single follicular units are transplanted with success when a portion of the stroma is also transplanted; however, overly aggressive trimming of tissue around the follicle results in their loss.37 The stromal dependency of BCC implies that embolic, potentially metastatic cells either carry their stroma with them to survive and proliferate or evolve a biological mechanism to support independent stromal proliferation in the new location. Dense fibrous stroma characterizes metastatic lesions of the bone, bone marrow, salivary and parotid glands, subcutaneous tissue, and especially those in lymph nodes, the most common site of metastasis (Figure 3A). However, the stroma of MBCC to the lung and liver, which are sites of hematogenous dissemination, is sparse.

Recent studies in melanoma, invasive breast cancer, non–small cell lung carcinoma, invasive prostate carcinoma, and head and neck squamous cell carcinoma have suggested that tumor angiogenesis (expressed as the microvessel density within the tumor and in areas adjacent to the tumor-stroma interface) significantly correlates with tumor aggressiveness and the overall survival of patients with solid tumors.3845 Tumor growth and metastasis are dependent on tumor neovascularization. Tumors may persist as asymptomatic lesions, but only vascularized tumors may grow rapidly and expand locally or metastasize.38,46

Staibano et al47 found that microvessel density is greater in the stroma of biologically aggressive BCC. In addition to the stromal influences, which are extrinsic to the cell, BCC may provide signals (intrinsic to the cell) to the stroma to transform fibroblasts at the borders of tumor nests into microvessels, which support tumor growth4767 (Table 2). In this case of metastatic BCC, microvessels defined by CD34 are particularly evident at the boundary of the tumor and stroma, at the invasive front of the lesion, and between thin sheets of invasive cells, even at a considerable distance from the principal tumor mass in the lymph node, which supports the theory that the tumor influences the stroma to produce the microvessels (Figure 3B and C). In theory, potentially metastatic cells either carry their stroma with them to survive and proliferate or evolve a biological mechanism to support independent stromal proliferation in the new location. This case of BCC metastatic to axillary lymph nodes illustrates that metastatic cells take stroma with the cells to proliferate and the pulmonary metastasis may represent the evolution of a mechanism to support independent stromal proliferation by intrinsic cell signals. Understanding the mechanisms of tumor growth by extrinsic and intrinsic signals may provide new therapeutic avenues.

Table 2. 
Factors Associated With Metastasis and/or Aggressive Growth of Basal Cell Carcinoma
Factors Associated With Metastasis and/or Aggressive Growth of Basal Cell Carcinoma
Back to top
Article Information

Corresponding author and reprints: June K. Robinson, MD, Division of Dermatology, Cardinal Bernardin Cancer Center, Loyola University Stritch School of Medicine, 2160 S First Ave, Room 341, Maywood, IL 60153 (e-mail: jrobin5@lumc.edu).

Accepted for publication September 10, 2002.

This study was supported in part by Division of Dermatology and Department of Pathology funds, Loyola University Stritch School of Medicine.

References
1.
Cotran  RS Metastasizing basal cell carcinoma. Cancer. 1961;141036- 1040Article
2.
Paver  KRoyser  KBurry  N  et al.  The incidence of basal cell carcinoma and their metastases in Australia and New Zealand [letter]. Australas J Dermatol. 1973;1453Article
3.
Scanlon  EFVolkmer  DOviedo  MA  et al.  Metastatic basal cell carcinoma. J Surg Oncol. 1980;15171- 180Article
4.
Weedon  DWall  D Metastatic basal cell carcinoma. Med J Aust. 1975;2177- 179
5.
Lakshmipathi  THunt  KM Metastasizing basal cell carcinoma. Br J Dermatol. 1967;79267- 270Article
6.
Miller  DLWeinstock  MA Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994;30774- 778Article
7.
Hoy  WE Nonmelanoma skin cancer in Albuquerque, New Mexico: experience of a major health care provided. Cancer. 1996;772489- 2495Article
8.
Zackheim  HS Origin of human basal cell epithelioma. J Invest Dermatol. 1963;40283- 297Article
9.
Brodland  DG Features associated with metastasis. Miller  SJMaloney  MEeds.Cutaneous Oncology London, England Blackwell Science Inc1998;657
10.
Pinkus  H Epithelial and fibroepithelial tumors. Arch Dermatol. 1965;9124- 37Article
11.
Beadles  CF Rodent ulcer. Trans Pathol Soc Lond. 1894;45176- 181
12.
Giri  DDGupta  PKHoda  RS Cytologic diagnosis of metastatic basal cell carcinoma: report of a case with immunocytochemical and molecular pathologic considerations. Acta Cytol. 2000;44232- 236Article
13.
Osterlind  AHjalgrim  HKulinsky  BFrentz  G Skin cancer as a cause of death in Denmark. Br J Dermatol. 1991;125580- 582Article
14.
Amonette  RASalasche  SJMc Chesney  TClarendon  CDDilawari  RA Metastatic basal cell carcinoma. J Dermatol Surg Oncol. 1981;7397- 400Article
15.
Dzubow  LM Metastatic basal cell carcinoma originating in the supra-parotid region. J Dermatol Surg Oncol. 1986;121306- 1308Article
16.
Von Domarus  HStevens  PJ Metastatic basal cell carcinoma: report of five cases and review of 170 cases in the literature. J Am Acad Dermatol. 1984;101043- 1060Article
17.
Farmer  ERHelwig  EB Metastatic basal cell carcinoma: a clinico-pathologic study of 17 cases. Cancer. 1980;46748- 757Article
18.
Assor  D Basal cell carcinoma with metastasis to bone. Cancer. 1967;202125Article
19.
Wermuth  BMFajardo  LF Metastatic basal cell carcinoma. Arch Pathol. 1970;90458- 462
20.
Soffer  DKaplan  HWeshler  Z Meningeal carcinomatosis due to basal cell carcinoma. Hum Pathol. 1985;16530Article
21.
Randle  HW Basal cell carcinoma: identification and treatment of the high-risk patient. Dermatol Surg. 1996;22255- 261
22.
Lo  JSSnow  SNReizner  GT  et al.  Metastatic basal cell carcinoma: reportof 12 cases and a review of the literature. J Am Acad Dermatol. 1991;24715- 719Article
23.
Snow  SNSahl  WLo  JS  et al.  Metastatic basal cell carcinoma: report of five cases. Cancer. 1994;73328- 335Article
24.
Menz  JSterrett  GWall  L Metastatic basal cell carcinoma associated with a small primary tumour. Australas J Dermatol. 1985;26121- 124Article
25.
Siegel  RJWood  T Nonrecurrent primary basal cell carcinoma of the lower extremity with late metastasis. J Dermatol Surg Oncol. 1994;20490- 493Article
26.
Mikhail  GRNims  LPKelly  AP  JrDitmars  DMEyler  WR Metastatic basal cell carcinoma. Arch Dermatol. 1977;1131261- 1269Article
27.
Safai  BGood  RA Basal cell carcinoma with metastasis. Arch Pathol Lab Med. 1977;101327- 331
28.
Otley  CCLim  KKRoenigk  RK Cure rates for cancer of the skin: basal cell carcinoma, squamous cell carcinoma, melanoma, and soft tissue sarcoma. Roenigk  RKRoengik  HHeds.Dermatologic Surgery New York, NY Marcel Dekker Inc1996;745- 753
29.
Asada  MSchaart  FMde Almeida  HL  Jr  et al.  Solid basal cell epithelioma (BCE) possibly originates from the outer root sheath of the hair follicle. Acta Derm Venereol. 1993;73286- 292
30.
Kruger  KBlume-Peytavi  UOrtanos  CE Basal cell carcinoma possible originates from the outer root sheath and/or the bulge region of the vellus hair follicle. Arch Dermatol Res. 1999;291253- 259Article
31.
Van Scott  EJReinertson  RP The modulating influence of the stromal environment on epithelial cells studied in human autotransplants. J Invest Dermatol. 1961;36109- 117
32.
Lyles  TWFreeman  RGKnox  JM Transplantation of basal cell epitheliomas. J Invest Dermatol. 1960;34353
33.
Blackwell  JBMcComb  H The long-term results of autologous transplantation of basal cell carcinoma in skin grafts. Cancer. 1969;23101- 108Article
34.
Gerstein  W Transplantation of basal cell epithelioma to the rabbit. Arch Dermatol. 1963;88834- 836Article
35.
Cooper  MPinkus  H Intrauterine transplantation of rat basal cell carcinoma as a model for reconversion of malignant to benign growth. Cancer Res. 1977;372544- 2552
36.
Grimwood  REGlanz  SMSiegle  RJ Transplantation of human basal cell carcinoma to C57/Balb/Cbg/bg-nu/nu (beige-nude) mouse. J Dermatol Surg Oncol. 1988;1459- 62Article
37.
Stough  DBJimenez  FJ Single hair grafting. Roenigk  RKRoengik  HHeds.Dermatologic Surgery New York, NY Marcel Dekker Inc1996;1205- 1211
38.
Srivastava  ALaidler  PDavies  RP  et al.  The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma: a quantitative histologic study. Am J Pathol. 1988;133419- 423
39.
Weidner  NSemple  JPWelch  WR  et al.  Tumor angiogenesis and metastasis: correlation in breast carcinoma. N Engl J Med. 1991;3241- 8Article
40.
Bosari  SLee  AKCDe Lillis  RA  et al.  Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol. 1992;23755- 761Article
41.
Kaldjian  EJin  LLloyd  R Immunohistochemical analysis of breast carcinomas: correlation of oestrogen and progesterone receptors, proliferative activity, tumor vascularity, and lymph node metastasis [abstract]. Mod Pathol. 1992;514A
42.
Horak  ELeek  RKlenk  N  et al.  Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet. 1992;3401120- 1124Article
43.
Weidner  NCarroll  PRFlax  J  et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143401- 409
44.
Weidner  N Tumor angiogenesis: basic concepts and review of current applications in tumor prognostication. Semin Diagn Pathol. 1993;10302- 313
45.
Folkman  J What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst. 1990;824- 6Article
46.
Liotta  LASteeg  PSStetler-Stevenson  WG Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991;64327- 336Article
47.
Staibano  SBoscaino  ASalvatore  GOrabona  PPalombini  LDe Rosa  G The prognostic significance of tumor angiogenesis in nonaggressive and aggressive basal cell carcinoma of the human skin. Hum Pathol. 1996;27695- 700Article
48.
Baum  R Expression of CD44 isoforms in basal cell carcinomas. Br J Dermatol. 1996;134465- 468Article
49.
Beer  T Ber Ep4 and epithelial membrane antigen aid distinction of basal cell, squamous cell and basosquamous carcinomas of the skin. Histopathology. 2000;37218- 223Article
50.
De Rosa  K Fibronectin, laminin, type IV collagen distribution and myofibroblastic stroma reaction in aggressive and nonaggressive basal cell carcinoma. Am J Dermatopathol. 1994;16258- 267Article
51.
Dumas  L Expression of basement membrane antigens and matrix metalloproteinaseses 2 and 9 in cutaneous basal and squamous cell carcinoma. Anticancer Res. 1999;192929- 2938
52.
Fuller  N Expression of E-cadaherin in human epidermal non-melanoma cutaneous tumors. Br J Dermatol. 1996;13428- 32Article
53.
Giri  J Cytologic diagnosis of metastatic basal cell carcinoma: report of a case with immunocytochemical and molecular pathologic considerations. Acta Cytol. 2000;44232- 236Article
54.
Horlock  NL Cellular proliferation characteristics do not account for the behaviour of horrifying basal cell carcinoma: a comparison of growth fraction of horrifying and nonhorrifying tumours. Br J Plast Surg. 1998;5159- 66Article
55.
Kanatakis  B Expression of the nm23 metastatsis-supressor gene product in tumors. J Cutan Pathol. 1997;24151- 156Article
56.
Leffell  DL Aggressive-growth basal cell carcinoma in young adults. Arch Dermatol. 1991;1271663- 1667Article
57.
Lifschitz-Mercer  BCzernobilsky  BFeldberg  EGeigas  B Expression of the adherens junction protein vinculin in human and squamous cell tumors: relationship to invasiveness and metastatic potential. Hum Pathol. 1997;281230- 1236Article
58.
de Faria  J Basal cell carcinoma of the skin with areas of squamous cell carcinoma: a basosquamous cell carcinoma? J Clin Pathol. 1985;381273- 1277Article
59.
Maloney  M What is basosquamous carcinoma? Dermatol Surg. 2000;26505- 506Article
60.
Morales-Ducret  CRvan de Rijn  MLeBrun  DPSmoller  BR Bcl-2 expression in primary malignancies of the skin. Arch Dermatol. 1995;131909- 912Article
61.
Pentel  MJ Cell surface molecules in basal cell carcinomas. Dermatol Surg. 1995;21858- 861
62.
Ramdial  MP Bcl-2 protein expression in aggressive and non-aggressive basal cell carcinomas. J Cutan Pathol. 2000;27283- 291Article
63.
Ratner  D Perineural spread of basal cell carcinomas treated with Mohs micrographic surgery. Cancer. 2000;881605- 1613Article
64.
Rossen  TT Expression of the alpha 6 beta 4 integrin by squamous cell carcinomas and basal cell carcinomas: possible relation to invasive potential? Acta Derm Venereol. 1994;74101- 105
65.
Seelentag  AG Cd44 standard and variant isofrom expression in human epidermal skin tumors is not correlated with tumor aggressiveness but does appear regulated during proliferation and tumor de-differentiation. Int J Cancer. 1996;69218- 224Article
66.
Spiers  MP Expression of plasminogen activators in basal cell carcinoma. J Pathol. 1996;178290- 296Article
67.
Wagner  R Differential expression of tissue inhibitor metalloproteinases-2 by cutaneous squamous and basal cell carcinomas. J Invest Dermatol. 1996;106321- 326Article
×